HIV1 p24 ELISA Kit ab218268 is a single-wash 90-min SimpleStep ELISA® used to quantify HIV1 p24 with a sensitivity of 1.1 pg/ml. The assay uses a simple Mix-Wash-Read protocol with just one incubation and wash step.
Easy-to-use, rapid, sensitive HIV1 p24 sandwich ELISA Kit:
Mix, Wash, Read: get results in 90 minutes with SimpleStep ELISA® format
Colorimetric assay - 450nm readout; works on any plate reader
Colorimetric
Cell culture extracts, Tissue Extracts, Heparin Plasma, Cell culture supernatant, Serum, EDTA Plasma
Sandwich (quantitative)
Human
4.69 - 300 pg/mL
1h 30m
= 1.1 pg/mL
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application sELISA | Reactivity Reacts | Dilution info - | Notes - |
Gag-Pol polyproteinMediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.Matrix protein p17Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).Capsid protein p24Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion (PubMed:8648689). Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (PubMed:12660176). Host restriction factors such as monkey TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (PubMed:23785198). Host PIN1 apparently facilitates the virion uncoating (By similarity). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid (PubMed:24554657).Nucleocapsid protein p7Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates in gRNA dimerization, packaging, tRNA incorporation and virion assembly.ProteaseAspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane (PubMed:9573231, PubMed:11932404). Cleavages take place as an ordered, step-wise cascade to yield mature proteins (PubMed:9573231, PubMed:11932404). This process is called maturation (PubMed:9573231, PubMed:11932404). Displays maximal activity during the budding process just prior to particle release from the cell (PubMed:9573231, PubMed:11932404). Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles (PubMed:7835426). Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (PubMed:12660176, PubMed:19914170). Also mediates cleavage of host YTHDF3. Mediates cleavage of host CARD8, thereby activating the CARD8 inflammasome, leading to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding (PubMed:32053707). Mediates cleavage of host CARD8, thereby activating the CARD8 inflammasome, leading to the clearance of latent HIV-1 in patient CD4(+) T-cells after viral reactivation; in contrast, HIV-1 can evade CARD8-sensing when its protease remains inactive in infected cells prior to viral budding (PubMed:33542150).Reverse transcriptase/ribonuclease HMultifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.IntegraseCatalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.
Gag-Pol polyprotein, Pr160Gag-Pol, gag-pol
HIV1 p24 ELISA Kit ab218268 is a single-wash 90-min SimpleStep ELISA® used to quantify HIV1 p24 with a sensitivity of 1.1 pg/ml. The assay uses a simple Mix-Wash-Read protocol with just one incubation and wash step.
Easy-to-use, rapid, sensitive HIV1 p24 sandwich ELISA Kit:
Mix, Wash, Read: get results in 90 minutes with SimpleStep ELISA® format
Colorimetric assay - 450nm readout; works on any plate reader
Gag-Pol polyprotein, Pr160Gag-Pol, gag-pol
Colorimetric
Cell culture extracts, Tissue Extracts, Heparin Plasma, Cell culture supernatant, Serum, EDTA Plasma
Sandwich (quantitative)
Human
4.69 - 300 pg/mL
1h 30m
Pre-coated microplate (12 x 8 well strips)
= 1.1 pg/mL
Sample | n | mean | SD | C.V. |
---|---|---|---|---|
Sample Overall | n 3 | mean - | SD - | C.V. 4.5 |
Sample | n | mean | SD | C.V. |
---|---|---|---|---|
Sample Overall | n 5 | mean - | SD - | C.V. 4.7 |
Sample type | Average % | Range |
---|---|---|
Sample type Serum | Average % = 105 | Range 94 - 117 % |
Sample type EDTA Plasma | Average % = 98 | Range 93 - 103 % |
Sample type Cell culture extracts | Average % = 107 | Range 103 - 113 % |
Sample type Heparin Plasma | Average % = 102 | Range 100 - 103 % |
Sample type Cell culture media | Average % = 102 | Range 94 - 107 % |
Blue Ice
+4°C
+4°C
HIV1 p24 ELISA Kit (ab218268) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of HIV1 p24 protein in human serum, plasma, cell culture supernatant, and cell and tissue extract samples. It uses our proprietary SimpleStep ELISA® technology. Quantitate HIV1 p24 with 1.1 pg/mL sensitivity.
Lentivirus vectors based on HIV-1 have gained popularity as a tool for cell and gene therapy, owing to their ability to carry and integrate a high volume of transgenes in a range of dividing and non-dividing cell types. Pseudo-lentiviral particles are typically produced from 293T cells and harvested from the medium 48-78hrs post-transfection. To ensure that the pseudoviral medium is viable, and to control the number of copies of integrated viral constructs per target cell, the viral titre needs to be determined before transduction experiments. Our HIV1 p24 SimpleStep ELISA® can be used to rapidly and sensitively determine the titre of HIV1 particles in range of sample types.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (Pre-coated 384 well Microplate SimpleStep ELISA® ab203359) is available to use as an alternative to the 96-well microplate provided with SimpeStep ELISA® kits.
ASSAY SPECIFICITY This kit recognizes both native and recombinant HIV-1 p24 protein in serum, EDTA and heparin plasma, cell culture supernatant, and cell and tissue extract samples only. Urine, saliva, and milk samples have not been tested with this kit.
CROSS REACTIVITY Recombinant HIV-1 Gag protein was prepared at 50 ng/mL and 1 ng/mL and assayed for cross reactivity. 1% cross-reactivity was observed.
HIV1 p24 (capsid) protein is essential for HIV-1 viral replication and for the HIV-1 infection of non-dividing cells. HIV1 p24 proteins form viral capsid that encapsulates the genomic HIV1 RNA. HIV1 p24 concentration in host plasma is commonly used as indicator of viral load. Upon the viral infection, the development of anti-HIV1 p24 host humoral responses leads to immune complex formation and reduction of the free HIV1 p24 concentration in circulation.
Lentivirus vectors based on HIV-1 have gained popularity as a tool for cell and gene therapy, owing to their ability to carry and integrate a high volume of transgenes in a range of dividing and non-dividing cell types. Pseudo-lentiviral particles are typically produced from 293T cells and harvested from the medium 48-78hrs post-transfection. To ensure that the pseudoviral medium is viable, and to control the number of copies of integrated viral constructs per target cell, the viral titre needs to be determined before transduction experiments. Our HIV1 p24 SimpleStep ELISA® can be used to rapidly and sensitively determine the titre of HIV1 particles in range of sample types.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
The p24 protein also known as the HIV-1 capsid protein or CA is an important component of the Human Immunodeficiency Virus Type 1 (HIV-1). It has a molecular weight of approximately 24 kDa. This protein is expressed in the viral core and plays a critical role in the virus's structural integrity. The p24 protein helps form the conical core that encases the viral RNA genome. Antibody-based detection of this protein is a common approach to study HIV often utilizing tools such as the p24 ELISA kit and p24 assay which are pivotal in early HIV detection and research.
The p24 protein is essential in the assembly and maturation of the HIV-1 virion. It forms part of the Gag polyprotein precursor which undergoes proteolytic cleavage to create the mature viral proteins necessary for the formation of infectious particles. The Gag polyprotein assembles into the immature virion and later cleaves into functional units including the matrix capsid and nucleocapsid proteins. This process ensures the viral core is capable of delivering the genetic material to the host cell during infection. Such assembly is important for maintaining the infective efficiency of the HIV-1 virus.
P24 plays an integral role in the lifecycle of HIV-1 especially in the virus replication and assembly pathways. It interacts with host cellular machinery to facilitate the viral assembly and is involved in the highly coordinated regulation of the viral life cycle. This protein shares pathway connections with other viral proteins such as p55 Gag and matrix protein p17 both of which also derive from the Gag polyprotein. These interactions underline the importance of p24 in the broader context of HIV-1's ability to propagate within host cells.
The p24 protein is directly linked to the pathogenesis of Acquired Immunodeficiency Syndrome (AIDS). Understanding and detecting the presence of p24 are vital for diagnosing and monitoring the progression of HIV-1 infection. Additionally it holds a significant relationship with immune system disorders due to the virus's effect on immune function. p24 detection is often a component in HIV ELISA and HIV p24 ELISA tests which measure the presence of the virus in the bloodstream. The protein also connects to the envelope glycoprotein gp120 which is involved in initial host cell binding and viral entry furthering its pivotal role in the progression of HIV-related diseases.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Interpolated concentrations of spike HIV1 p24 in human serum, human plasmas, and rhesus macaque plasma.
The concentrations of HIV1 p24 were measured in duplicates, interpolated from the HIV1 p24 standard curves and corrected for sample dilution. Undiluted samples are as follows: human serum 100% (neat), human plasma (heparin) 100% (neat), human plasma (EDTA) 100% (neat), and rhesus macaque plasma (EDTA) 100% (neat). The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2).
Interpolated concentrations of spike HIV1 p24 in Jurkat Cell Extract and RPMI + 10% FBS cell culture media.
The concentrations of HIV1 p24 were measured in duplicates, interpolated from the HIV1 p24 standard curves and corrected for sample dilution. Undiluted samples are as follows: Jurkat cell extract 100 μg/mL, RPMI + 10% FBS cell culture media 100% (neat). The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2).
Serial dilutions of recombinant HIV1 p24 were prepared within the working range of the assay and assayed for reactivity.
Serial dilutions of recombinant HIV1 p24 (group M, subtype B, strain 92418), HIV1 p24 (group M, subtype C, strain 92BR025) and HIV1 p24 (group O, strain BCF06) were prepared within the working range of the assay and assayed for reactivity. O.D. values within the linear range of each protein are graphed.
Acid treatment recovery.
Three concentrations of purified HIV-1 p24 protein were spiked in duplicate to the indicated biological matrix and treated with the Acid Treatment Protocol to evaluate signal recovery in the working range of the assay. The signals of the same concentrations of purified HIV-1 p24 protein spiked in duplicate to Sample Diluent 50BS and treated with the Acid Treatment Protocol were taken as 100%.
Acid treatment effect.
Single concentrations of purified HIV-1 p24 protein were spiked in duplicate to the indicated biological matrix and treated with the Acid Treatment Protocol or mock acid treated to evaluate the effect of the Acid Treatment Protocol on the signal. The signals of single concentrations of purified HIV-1 p24 protein spiked in duplicate to the indicated biological matrix and mock acid treated were taken as 100%.
Acid treatment recovery of synthetic complexes.
Single concentrations of purified HIV-1 p24 protein were spiked to the indicated biological matrix, pre-incubated with unlabeled capture and detector antibodies or unrelated antibodies and treated with the Acid Treatment Protocol to evaluate the signal recovery of p24 complexed with interfering antibodies by Acid Treatment Protocol. The signals of single concentrations of purified HIV-1 p24 protein spiked to the indicated biological matrix, preincubated with unrelated antibodies and treated with the Acid Treatment Protocol were taken as 100%. There were no signals if the single concentrations of purified HIV-1 p24 protein were spiked to the indicated biological matrix, pre-incubated with the unlabeled capture and detector antibodies and mock acid treated, indicating that the unlabeled capture and detector antibodies efficiently formed synthetic immune complexes with HIV-1 p24 and completely blocked the signals.
Linearity of dilution – spiked Purified HIV-1 p24 in Human serum, plasma (heparin, citrate, EDTA) and rhesus macaque EDTA plasma.
Purified HIV-1 p24 was spiked into biological samples and diluted in a 2-fold dilution series in Sample Diluent 50BS.
Linearity of dilution – spiked purified HIV-1 p24 in FBS cell culture media and Jurkat Cell Extract.
Purified HIV-1 p24 was spiked into biological samples and diluted in a 2-fold dilution series in Sample Diluent NS for cell culture media and 1X Cell Extraction Buffer PTR for cell extract samples.
Example of HIV1 p24 standard curve in Sample Diluent NS.
Background-subtracted data values (mean +/- SD) are graphed.
Raw data values for Example of HIV-1 p24 standard curve in Sample Diluent 50BS.
Raw data values are shown in the table
Example of HIV1 p24 standard curve in 1X Cell Extraction Buffer PTR.
Background-subtracted data values (mean +/- SD) are graphed.
Example of HIV-1 p24 standard curve in 1X Cell Extraction Buffer PTR.
Raw data values are shown in the table
Raw data values for example of HIV-1 p24 standard curve in Sample Diluent NS.
Raw data values are shown in the table
Example of HIV1 p24 standard curve in Sample Diluent 50BS.
Background-subtracted data values (mean +/- SD) are graphed.
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com